New, Portable Pattern Scanning Laser (PASCAL) offers photo-thermal stimulating Endpoint Management Technology
July 23, 2013 - SANTA CLARA, CA - Topcon Medical Laser Systems today announced 510(k) clearance of the PASCAL Synthesis - a portable, dual-port pattern-scanning laser available in either 532 nm or 577 nm wavelengths. Synthesis is designed to integrate with Topcon D7 and Haag-Streit style slit lamps*, with pricing similar to a premium single spot laser system. Synthesis will allow fast and effective treatment of retinal disorders using clinically proven PASCAL technology, while offering physicians the option of keeping their current slit lamp set-up.
“The introduction of the PASCAL Synthesis will, for the first time, offer physicians a more cost-effective solution in providing their patients pattern-scanning laser technology,” says Tom Koike, President and CEO at Topcon Medical Laser Systems. “And with Endpoint Management available as an upgrade on all Synthesis lasers, physicians will have the option to treat at sub-threshold levels for less-damaging treatment of a variety of retinal diseases.”
Prof. Paolo Stanga from Manchester Royal Eye Hospital explains: “The Synthesis is ideal for physicians looking for an intuitive and clinically effective laser to provide pattern-scanning delivery.” He adds: “ Having the versatility of different treatment options, such as a single-spot laser and pattern scanning with Endpoint Management is very advantageous when treating a disease-diverse patient base.”
The marriage of these two technologies, Synthesis and Endpoint Management, allows for greater control, efficiency and precision, resulting in positive therapeutic outcomes at non-damaging treatment levels. “It is an additional step towards offering our customers new and improved technologies that not only complement their laser treatment portfolio, but provide greater clinical benefits for their patients,” says Koike.
About Topcon Medical Laser Systems (TMLS):
Located in Santa Clara, CA, the company was founded in January 2004 to develop a new technology for the treatment of ocular disease. Initially developed at Stanford University, and exclusively licensed to TMLS, PASCAL Photocoagulators (Pattern Scanning Lasers) are used to treat a variety of retinal conditions including diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusive disease.
Company Contact
Greg Fava | Senior Director of Marketing
[email protected]
Media Contact
Mike Elofer |Pascale Communications
[email protected]
484-620-6167